poliovirus vaccines

Also found in: Dictionary, Thesaurus.
Related to poliovirus vaccines: poliomyelitis vaccine

po·li·o·vi·rus vac·cines

1. inactivated poliovirus vaccine (IPV), an aqueous suspension of inactivated strains of poliomyelitis virus (types 1, 2, and 3) used by injection; has largely been replaced by the oral vaccine;
2. oral poliovirus vaccine (OPV), an aqueous suspension of live, attenuated strains of poliomyelitis virus (types 1, 2, and 3) given orally for active immunization against poliomyelitis.
Farlex Partner Medical Dictionary © Farlex 2012
References in periodicals archive ?
National coverage levels for the third dose of poliovirus vaccine (Pol3) delivered through routine immunization services by age 12 months have been <60% since 2002, * with lower rates in northern states.
Current Advisory Committee on Immunization Practices (ACIP) recommendations specify 4 doses of trivalent inactivated poliovirus vaccine (IPV) at ages 2 months, 4 months, 6-18 months, and 4-6 years.
Vaccination; poliovirus vaccine; immunization schedule; child welfare.
In 2017, a total of 172 SIAs were conducted in five World Health Organization (WHO) regions, during which nearly 1.8 billion total OPV and inactivated poliovirus vaccine (IPV) doses were allocated for use; 161 SIAs were conducted in 2018, with approximately 1.7 billion bOPV and IPV doses.
A global, synchronized switch to bivalent oral poliovirus vaccine (bOPV, types 1 and 3 only) was completed in April 2016.
IPV is the only poliovirus vaccine recommended for immunocompromised persons and their household contacts.
This progress has been achieved through widespread use of oral poliovirus vaccine (OPV), most commonly trivalent OPV (tOPV), which contains types 1, 2, and 3 live, attenuated polioviruses.
The cost of Pediarix is currently 4%-5% above the combined cost of DTaP, hepatitis B (recombinant), and inactivated poliovirus vaccines, said Dr.
Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study.
A resurgence in wild poliovirus (WPV) transmission occurred in Nigeria during 2003-2004 after a loss of public confidence in oral poliovirus vaccine (OPV) and suspension of supplementary immunization activities (SIAs) * in several northern states (1).
In January 1997, the Food and Drug Administration (FDA) approved an amendment to the package labeling for the inactivated poliovirus vaccine (IPV) currently licensed in the United States, allowing the third dose of this IPV in an all-IPV schedule to be administered as early as age 6 months.
In addition, poliovirus vaccine has been offered to members of all unvaccinated communities.